Accessibility Menu
BioHarvest Sciences logo

BioHarvest Sciences(NASDAQ) BHST

Market Cap$39.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-75%
5 Year-81%
1 Year-71%
1 Month-21%
$2.16
+0.00%
+0.00Today
After hours$2.28+$0.12 (+5.56%)
BioHarvest Sciences last closing stock price
MetricPriceDate
Last closeUSD 2.262026-08-04
BioHarvest Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.78%USD 2.042026-07-28
1 month-21.25%USD 2.872026-07-02
3 month-46.19%USD 4.202026-05-06
Year to date-56.45%USD 5.192025-12-31
1 year-70.53%USD 7.672025-08-04
3 year-52.87%USD 4.802023-08-04
5 year-81%USD 11.902021-08-05
Since inception-75.46%USD 8.802020-04-23

BioHarvest Sciences Financials at a Glance

Market Cap

$39.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$35.16M

Net Income (TTM)

-$11.44M

EPS (TTM)

-$0.60

P/E Ratio

-3.79

Dividend

$0.00

Beta (Volatility)

-29.68 (Low)

Price

$2.16

Volume

100,272

Open

$2.17

Previous Close

$2.26

Daily Range

$2.15 - $2.29

52-Week Range

$1.82 - $12.80

Estimated Earnings Date

Aug 11, 2026

BHST News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotechnology firm specializing in the development of nutraceuticals and pharmaceuticals. The company utilizes a proprietary botanical synthesis platform to cultivate active ingredients from plant cells, creating clinically validated therapeutic products.

Products and Services
  • VINIA, a dietary supplement derived from red grape cells
  • Contract development and manufacturing services for third parties
  • Evidence-based therapeutic products for health and wellness
Growth Outlook
  • Revenue of $8.5 million reported in Q1 2026, showing strong market demand
  • Consistent product innovation expected to drive future sales growth
  • Expansion into new markets in the U.S. and Israel enhances growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of $34.3 million indicates solid performance
  • Current ratio of 2.96 suggests strong liquidity position
  • Cash and cash equivalents of $19.2 million provide operational flexibility
BioHarvest Sciences Inc. operates in a dynamic sector, leveraging advanced technology to create unique health products. The company's flagship product, VINIA, has gained traction in the wellness market, contributing to its revenue growth. Recent financial results indicate a robust liquidity position, with a current ratio significantly above 1, suggesting the ability to meet short-term obligations. The company’s focus on innovation and market expansion positions it well for future growth, making it an intriguing option for investors interested in the biotechnology sector.
AI Generated • Jul 20, 2026

Industry

Personal Products

Sector

Consumer Staples

Employees

89

CEO

Ilan Sobel

Website

www.bioharvest.com

Headquarters

Vancouver, BC V6C 2T6, CA

BHST Financials

Key Financial Metrics (TTM)

Gross Margin

59.50%

Operating Margin

-16.19%

Net Income Margin

-32.54%

Return on Equity

-88.01%

Return on Capital

-14.10%

Return on Assets

-25.11%

Earnings Yield

-26.39%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$39.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

17.33M

Volume

100.27K

Avg. Volume

42.13K

Financials (TTM)

Gross Profit

$20.92M

Operating Income

-$5.69M

EBITDA

-$6.68M

Operating Cash Flow

-$7.45M

Capital Expenditure

-$2.29M

Free Cash Flow

-$9.74M

Cash & ST Invst.

$19.17M

Total Debt

$16.42M

BioHarvest Sciences Performance Analysis

BioHarvest Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,498,000161.6%
20232023-12-31USD 12,672,000130.5%
20242024-12-31USD 25,188,00098.8%
20252025-12-31USD 34,508,00037.0%
BioHarvest Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-308.3%
Q32025-09-306.5%
Q42025-12-31-0.0%
Q12026-03-31-6.2%
BioHarvest Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.869.0%
20232023-12-31USD -0.937.9%
20242024-12-31USD -0.80-14.1%
20252025-12-31USD -0.60-24.2%
BioHarvest Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-84.6%
Q32025-09-3041.7%
Q42025-12-3114.3%
Q12026-03-31N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.51M

+8.2%

Gross Profit

$5.04M

+9.6%

Gross Margin

59.21%

N/A

Market Cap

$39.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$440.01K

N/A

Employees

89

N/A

Net Income

-$2.64M

-13.0%

EBITDA

-$1.29M

+2.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$19.17M

+463.6%

Total Debt

$16.42M

-3.9%

Accounts Receivable

$3.18M

+42.6%

Inventory

$4.97M

+23.9%

Long Term Debt

$12.96M

+51.8%

Short Term Debt

$3.46M

-59.6%

Return on Assets

-25.11%

N/A

Return on Invested Capital

-15.81%

N/A

Free Cash Flow

-$2.17M

-2.8%

Operating Cash Flow

-$1.58M

-10.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MERCMercer International Inc.
$0.71+5.96%
BIOXBioceres Crop Solutions Corp.
$0.38+2.41%
LVROLavoro Limited
$0.13+0.00%
AVDAmerican Vanguard Corporation
$2.49+1.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
PLTRPalantir Technologies
$162.66+0.29%
SPCXSpace Exploration Technologies
$125.33+0.09%
NVDANvidia
$211.94+0.03%
INTCIntel
$100.86+0.11%

Questions About BHST

What is the current price of BioHarvest Sciences?

BioHarvest Sciences is trading at $2.26 per share.

What is the 52-week range for BioHarvest Sciences?

Over the past 52 weeks, BioHarvest Sciences has traded between $1.82 and $12.80.

How much debt does BioHarvest Sciences have?

As of the most recent reporting period, BioHarvest Sciences reported total debt of $16.42M.

How much cash does BioHarvest Sciences have on hand?

BioHarvest Sciences reported $19.17M in cash and cash equivalents in its most recent financial results.

What is BioHarvest Sciences’s dividend yield?

BioHarvest Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services